Modelling Tumor Treating Fields for the treatment of lung-based tumors

Tumor Treating Fields (TTFields), low-intensity electric fields in the frequency range of 100-500 kHz, exhibit antimitotic activity in cancer cells. TTFields were approved by the U. S. Food and Drug Administration for the treatment of recurrent glioblastoma in 2011. Preclinical evidence and pilot studies suggest that TTFields could be effective for treating certain types of lung cancer, and that treatment efficacy depends on the electric field intensity. To optimize TTFields delivery to the lungs, it is important to understand how TTFields distribute within the chest. Here we present simulations showing how TTFields are distributed in the thorax and torso, and demonstrate how the electric field distribution within the body can be controlled by personalizing the layout of the arrays used to deliver the field.

[1]  P. Hua,et al.  Measuring lung resistivity using electrical impedance tomography , 1992, IEEE Transactions on Biomedical Engineering.

[2]  Miklos Pless,et al.  A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. , 2013, Lung cancer.

[3]  Moshe Giladi,et al.  Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo. , 2014, Seminars in oncology.

[4]  P. Basser,et al.  Predicting the electric field distribution in the brain for the treatment of glioblastoma , 2014, Physics in medicine and biology.

[5]  Olaf Dössel,et al.  Ranking the Influence of Tissue Conductivities on Forward-Calculated ECGs , 2010, IEEE Transactions on Biomedical Engineering.

[6]  E. Kirson,et al.  Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields. , 2014, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[7]  P. Gutin,et al.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. , 2012, European journal of cancer.

[8]  C. Gabriel.  Dielectric properties of biological tissue: Variation with age , 2005, Bioelectromagnetics.

[9]  E. Dekel,et al.  Disruption of cancer cell replication by alternating electric fields. , 2004, Cancer research.

[10]  E. Dekel,et al.  Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors , 2007, Proceedings of the National Academy of Sciences.

[11]  Eva M. Schmelz,et al.  Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo , 2016, International journal of cancer.

[12]  R. W. Lau,et al.  The dielectric properties of biological tissues: III. Parametric models for the dielectric spectrum of tissues. , 1996, Physics in medicine and biology.

[13]  E. Kirson,et al.  Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs , 2009, Clinical & Experimental Metastasis.

[14]  Charles Scott,et al.  NT-40Interim Analysis of the EF-14 Trial: A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM , 2014 .